Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Japan”

A Study of TAK-360 in People With Narcolepsy or Idiopathic HypersomniaRecruiting
NCT07646678Phase 2, Phase 3Updated Aug 21, 2026
Sponsor: Takeda
Idiopathic Hypersomnia · Narcolepsy Type 1 · Narcolepsy Type 2
United States, China, Japan
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)Recruiting
NCT06841354Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Triple Negative Breast Neoplasms
United States, Argentina, Australia, Belgium, Brazil +29 more
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to EfgartigimodRecruiting
NCT07284420Phase 2Updated Aug 21, 2026
Sponsor: argenx
AChR-Ab Seropositive Generalized Myasthenia Gravis · Myasthenia Gravis · MG · gMG
United States, Belgium, Germany, Greece, Italy +3 more
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the HeartRecruiting
NCT06935370Phase 3Updated Aug 21, 2026
Sponsor: Boehringer Ingelheim
Heart Failure
United States, Argentina, Belgium, Brazil, Bulgaria +24 more
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:Recruiting
NCT07186101Phase 2Updated Aug 21, 2026
Sponsor: Eli Lilly and Company
Ulcerative Colitis
United States, Austria, Brazil, Canada, China +12 more
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsRecruiting
NCT07195695Phase 3Updated Aug 21, 2026
Sponsor: Boehringer Ingelheim
Non-small Cell Lung Cancer
United States, Argentina, Australia, Austria, Belgium +23 more
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeRecruiting
NCT07153471Phase 3Updated Aug 21, 2026
Sponsor: Eli Lilly and Company
Osteoarthritis
United States, Canada, China, Germany, India +3 more
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal CancerRecruiting
NCT06820463Phase 2Updated Aug 21, 2026
Sponsor: AbbVie
Metastatic Colorectal Cancer
United States, Australia, Austria, Brazil, Canada +9 more
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)Recruiting
NCT06997497Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Colon Adenocarcinoma · Rectal Adenocarcinoma
United States, Argentina, Australia, Brazil, Canada +24 more
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecruiting
NCT07218341Phase 4Updated Aug 21, 2026
Sponsor: Eli Lilly and Company
Chronic Lymphocytic Leukemia · Lymphoma, Small Lymphocytic
United States, Australia, Austria, Belgium, Canada +12 more
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)Recruiting
NCT06717347Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Diffuse Large B-Cell Lymphoma
United States, Argentina, Australia, Belgium, Brazil +30 more
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)Recruiting
NCT07116967Phase 3Updated Aug 21, 2026
Sponsor: Bristol-Myers Squibb
Plaque Psoriasis
United States, Argentina, Australia, Belgium, Brazil +20 more
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Recruiting
NCT06393374Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Triple-Negative Breast Cancer
United States, Argentina, Australia, Austria, Belgium +26 more
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid TumorsRecruiting
NCT05797168Phase 1, Phase 2Updated Aug 21, 2026
Sponsor: AstraZeneca
Ovarian Cancer · Lung Adenocarcinoma · Endometrial Cancer · Lung Squamous Cell Carcinoma
United States, Australia, Canada, China, Germany +7 more
A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3Active Not Recruiting
NCT04429087Phase 1Updated Aug 21, 2026
Sponsor: Boehringer Ingelheim
Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3
United States, Germany, Japan, Spain
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)Recruiting
NCT07221253Phase 3Updated Aug 21, 2026
Sponsor: AstraZeneca
Biliary Tract Cancer
United States, Australia, Belgium, Brazil, Canada +14 more
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)Active Not Recruiting
NCT05639114Phase 3Updated Aug 21, 2026
Sponsor: Novartis Pharmaceuticals
Systemic Lupus Erythematosus
United States, Argentina, Brazil, Bulgaria, Canada +14 more
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)Recruiting
NCT06430801Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Crohn's Disease
United States, Australia, Austria, Belgium, Brazil +42 more
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's DiseaseRecruiting
NCT06226883Phase 2Updated Aug 21, 2026
Sponsor: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Inflammatory Bowel Diseases · Crohn's Disease
United States, Australia, Austria, Bosnia and Herzegovina, Brazil +23 more
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)Recruiting
NCT06623422Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
United States, Argentina, Australia, Belgium, Brazil +26 more
Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction CancersRecruiting
NCT05205343N/AUpdated Aug 21, 2026
Sponsor: M.D. Anderson Cancer Center
Gastrostomy · Gastric · GastroEsophageal Cancer
United States, Japan, South Korea
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus ErythematosusRecruiting
NCT06617325Phase 3Updated Aug 21, 2026
Sponsor: UCB Biopharma SRL
Systemic Lupus Erythematosus
United States, Argentina, Belgium, Canada, Chile +17 more
A Study of LY3971297 in Participants With Heart FailureRecruiting
NCT07547540Phase 1Updated Aug 21, 2026
Sponsor: Eli Lilly and Company
Heart Failure · Heart Failure, Diastolic · Heart Failure, Systolic
United States, Japan, Moldova, Netherlands, Romania
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)Recruiting
NCT06077760Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
United States, Argentina, Australia, Belgium, Brazil +28 more
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With AchondroplasiaRecruiting
NCT07441876Phase 2, Phase 3Updated Aug 21, 2026
Sponsor: BioMarin Pharmaceutical
Achondroplasia
United States, Australia, Canada, Italy, Japan +4 more

Previous page Next page